US3962433A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment of calcium disorders using phosphonoalkane-polycarboxylic acids
Assignee: Henkel AG and Co KGaA
•
Filing: 1974-12-03
•
Granted: 1976-06-08
•
Expires: 1994-12-03
Abstract
Abstract A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficutly soluble calcium salts in the body of warm-blooded animals which consists of administering orally, parenterally or topically to said warm-blooded animals, a safe but effective amount of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid and water-soluble salts thereof.
Inventors
- 👤 Karl-Heinz Worms
- 👤 Christian Gloxhuber
- 👤 Manfred Schmidt-Dunker
- 👤 Helmut Blum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 14:17
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3839; C07F9/3869; A; A61; A61K; A61K31/00; A61K31/66; C07F9/3808
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
139 words
A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts in the body of warm-blooded animals which consists of administering orally or parenterally to said warm-blooded animals, a safe but effective amount for said treatment of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU9## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of ##EQU10## and ##EQU11## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, -CH 2 -CHRCOOH, -CH 2 -CHRPO 3 H 2 and ##EQU12## and B. a non-toxic pharmacologically acceptable water-soluble salt of (A).
Claim 2
Independent Claim
139 words
A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts in the body of warm-blooded animals which consists of administering orally or parenterally to said warm-blooded animals, a safe but effective amount for said treatment of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU9## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of ##EQU10## and ##EQU11## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, -CH 2 -CHRCOOH, -CH 2 -CHRPO 3 H 2 and ##EQU12## and B. a non-toxic pharmacologically acceptable water-soluble salt of (A).
Claim 3
Dependent Claim
26 words
The method of claim 1 wherein said phosphonoalkane-polycarboxylic acid is administered in a daily amount of from 0.05 to 500 mg/kg of the animal body weight.
Claim 4
Independent Claim
134 words
A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts in the body of warm-blooded animals which consists of administering orally or parenterally to said warm-blooded animals, a safe but effective amount for said treatment of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid derivative being a member selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU13## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of ##EQU14## and whrein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, and -CH 2 -CHRCOOH, and B. a non-toxic pharmacologically acceptable water-soluble salt of (A).
Claim 5
Independent Claim
134 words
A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts in the body of warm-blooded animals which consists of administering orally or parenterally to said warm-blooded animals, a safe but effective amount for said treatment of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid derivative being a member selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU13## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of ##EQU14## and whrein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, and -CH 2 -CHRCOOH, and B. a non-toxic pharmacologically acceptable water-soluble salt of (A).
Claim 6
Dependent Claim
26 words
The method of claim 3 wherein said phosphonoalkane-polycarboxylic acid is administered in a daily amount of from 0.05 to 500 mg/kg of the animal body weight.
Claim 7
Dependent Claim
23 words
The method of claim 3 wherein R is CH 3 , R 1 is PO 3 H 2 and R 2 is hydrogen.
Claim 8
Dependent Claim
27 words
The method of claim 3 wherein R is hydrogen, R 1 is PO 3 H 2 and R 2 is -CH 2 -CHRCOOH, R again being hydrogen.
Claim 9
Independent Claim
173 words
A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts in the body of warm-blooded animals which consists of administering orally or parenterally to said warm-blooded animals, a safe but effective amount for said treatment of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid derivative being a member selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU15## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of PO 3 H 2 ##EQU16## and ##EQU17## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, -CH 2 CHRCOOH, -CH 2 -CHRPO 3 H 2 and ##EQU18## with the proviso that R 1 and R 2 are selected so that at least two PO 3 H 2 groups are present in the molecule, and B. a non-toxic pharmacologically acceptable water-soluble salt of (A).
Claim 10
Independent Claim
173 words
A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts in the body of warm-blooded animals which consists of administering orally or parenterally to said warm-blooded animals, a safe but effective amount for said treatment of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid derivative being a member selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU15## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of PO 3 H 2 ##EQU16## and ##EQU17## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, -CH 2 CHRCOOH, -CH 2 -CHRPO 3 H 2 and ##EQU18## with the proviso that R 1 and R 2 are selected so that at least two PO 3 H 2 groups are present in the molecule, and B. a non-toxic pharmacologically acceptable water-soluble salt of (A).
Claim 11
Dependent Claim
26 words
The method of claim 7 wherein said phosphonoalkane-polycarboxylic acid is administered in a daily amount of from 0.05 to 500 mg/kg of the animal body weight.
Claim 12
Dependent Claim
132 words
A pharmaceutical composition for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essential of an effective amount of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid selected from the group consisting of A. at least one phosphonoalkane-carboxylic acid of the formula ##EQU19## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of PO 3 2 ##EQU20## and ##EQU21## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, -CH 2 -CHRCOOH, -CH 2 -CHRPO 3 H 2 and ##EQU22## and B. a non-toxic pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients.
Claim 13
Dependent Claim
132 words
A pharmaceutical composition for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essential of an effective amount of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid selected from the group consisting of A. at least one phosphonoalkane-carboxylic acid of the formula ##EQU19## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected from the group consisting of PO 3 2 ##EQU20## and ##EQU21## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, -CH 2 -CHRCOOH, -CH 2 -CHRPO 3 H 2 and ##EQU22## and B. a non-toxic pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients.
Claim 14
Dependent Claim
125 words
A pharmaceutical composition for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essentially of an effective amount of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU23## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected froam the group consisting of PO 3 H 2 and ##EQU24## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, and -CH 2 CHRCOOH, and B. a non-toxic pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients.
Claim 15
Dependent Claim
125 words
A pharmaceutical composition for the treatment of diseases relating to the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essentially of an effective amount of at least one pharmacologically acceptable phosphonoalkane-polycarboxylic acid selected from the group consisting of A. at least one phosphonoalkane-polycarboxylic acid of the formula ##EQU23## wherein R is selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, wherein R 1 is selected froam the group consisting of PO 3 H 2 and ##EQU24## and wherein R 2 is selected from the group consisting of hydrogen, alkyl having 1 to 3 carbon atoms, and -CH 2 CHRCOOH, and B. a non-toxic pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients.
References Cited (Backward Citations)
US3584124A
Cited
US3683080A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-08 | 1979-12-08 | 1980-06-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-08 | 1983-12-08 | 1984-06-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-08 | 1987-12-08 | 1988-06-08 | $7700.00 | Window Closed / Lapsed |